Loading
A university teaching hospital in Sousse with a radiotherapy service and a breast unit that treats about 350 new breast cancers a year. It is a site for international cancer and blood disorder trials.
IAEA DIRAC's equipment report, read on 11 November 2026 with the entry last updated in 2023, lists the radiotherapy service of Hôpital Farhat Hached in Sousse with one linear accelerator, one cobalt-60 unit and a CT scanner, and no brachytherapy unit. The Breast Centres Network directory (last modified March 2022) lists its breast unit with about 350 new breast cancer cases a year and a multidisciplinary team of radiologists, surgeons, pathologists, medical oncologists, radiotherapists and nurses, with a European certification in breast surgical oncology valid to 22 November 2026. ClinicalTrials.gov lists it as a site of the trial of inavolisib with pertuzumab and trastuzumab in PIK3CA-mutated HER2-positive breast cancer (NCT05894239) and of the long-term luspatercept safety study (NCT04064060). Its own website did not answer.
Shares A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer, Institut Salah Azaïez, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/